IUGNF - Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial

(NewsDirect)

Imugene Ltd (ASX:IMU)CEO Leslie Chong sits down with Jonathan Jackson in the Proactivestudio to delve into the company’s latest milestone - commencementof dosing for the first patient in the intravenous monotherapy arm ofa Phase 1 clinical trial of the CD19 oncolytic virotherapy drugcandidate, onCARlytics (also known as on-CAR-19, CF33-CD19HOV4).

DubbedOASIS, the trial focuses on adult patients grappling with advanced ormetastatic solid tumours. The trial's primary objective is toassess the safety and efficacy of two administration routes:intratumoural (IT) injection and intravenous (IV) infusion, eitherindependently or in conjunction with blinatumomab, a CD19-targetingbispecific monoclonal antibody (marketed as Blincyto® byAmgen).

Thecombination arm of the study will merge onCARlytics with blinatumomab,presenting a promising avenue for patients who previously foundlimited benefit from Blincyto® therapy alone.

Imugene'sgroundbreaking work is garnering attention, with the company recentlyfeatured on Channel 7.

Chong said:“We’re pleased to see onCARlytics continue to advance in theclinic after the first patient on the trial was dosed in late October,and this move into intravenous administration marks another milestonein our mission to bring innovative cancer treatments to patients inneed. With the combination arm of the study still to come, we eagerlyawait the chance to see more on the potential onCARlyticsholds."

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

jonathan@proactiveinvestors.com

Copyright (c) 2024 TheNewswire - All rights reserved.